Octavus Consulting- Evidence-Based Consulting Services.

Call us: +91 87500 88882

Email us: bd@octavusconsulting.com

Contact Us
Contact Us

Babli Singh

  • Home
  • Author: Babli Singh
20
Apr
No Comments

Q2W Newsletter: Apr’26 Part 1

Key Outcomes: Lilly’s Foundayo (orforglipron) – 1st GLP-1 weight-loss pill with no food/water restrictions, ~$25/mos with insurance Dupixent – EU approved for CSU in kids aged 2–11, 1st targeted therapy for this group Neffy nasal spray – 1st needle-free epinephrine approved in Canada for anaphylaxis YUVIWEL – orphan drug exclusivity granted for achondroplasia in kids […]
Continue Reading
15
Jan
No Comments

Q2W Newsletter: Jan’26 Part 1

Key Outcomes: Daiichi initiated P3 of Datopotamab deruxtecan (Datroway) for NSCLC, Pfizer’s P3 BREAKWATER study showed promising combinations in BRAF V600E mCRC, reinforcing global ADC and targeted therapy focus Biopharma deal-making remained strong across oncology and immunology, with multiple high-value licensing and collaboration agreements Pipeline momentum was robust in neurology and rare diseases, as Eisai/Biogen […]
Continue Reading
15
Dec
No Comments

Animal Health 2025 | Market Trends & Innovations Explained – Octavus Insights Corner

Insights Details Month: Oct 25 Tags: Animal Health, Conference, Pre-clinical, Phase 1, Phase 2, Phase 3, US FDA, Europe, Company Profile, Product profile, Deal Analysis, Funding Analysis, Landscape, Livestock Animals, Companion Animals, Top Diseases, Grooming & Smart Health Monitoring Device, Economic Impact, Emerging Technology, Artificial Intelligence, Digital Technology, Policy, USA, Veterinary Clinical Trials, Global Market […]
Continue Reading
29
Oct
No Comments

Learning from Trial Failures: Turning Setbacks into Strategic Data Assets

Every company has a “Phase III heartbreak.” The molecule looked perfect-mechanism sound, safety profile strong- but the primary endpoint missed. Most teams bury the data. At Octavus Consulting, we treat it as a gold mine. The Opportunity in Failure Clinical failures hold information about trial design, recruitment, and patient heterogeneity that can redefine the next […]
Continue Reading

Subscribe Newsletter

Sign up to receive notifications about the latest news and events from us!